LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

Petrie, John; Marso, Steven; Bain, Stephen; Franek, Edward; Jacob, Stephan; Masmiquel, Luis; Leiter, Lawrence; Haluzik, Martin; Satman, İlhan; Omar, Mohamed; Shestakova, Marina; Van Gaal, Luc; Mann, Johannes; Baeres, Florian; Zinman, Bernard; Poulter, Neil

doi:10.1097/hjh.0000000000000890

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

Petrie J. R., Marso S. P., Bain S. C., Franek E., Jacob S., Masmiquel L., ...Daha Fazla

JOURNAL OF HYPERTENSION, cilt.34, sa.6, ss.1140-1150, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 34 Sayı: 6
Basım Tarihi: 2016
Doi Numarası: 10.1097/hjh.0000000000000890
Dergi Adı: JOURNAL OF HYPERTENSION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1140-1150
Anahtar Kelimeler: blood pressure, cardiovascular disease, glucagon-like peptide-1, regional differences, targets, type 2 diabetes mellitus, EUROPEAN-SOCIETY, HYPERTENSION MANAGEMENT, OUTCOMES, LIRAGLUTIDE, COMBINATION, PREVENTION, GUIDELINES, METFORMIN, WEIGHT, SAFETY
İstanbul Üniversitesi Adresli: Evet

Özet

Objective: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial.